Explore 3 Stock Ideas & Industry Insights Download Free Report

Stocks

Ubiquiti Inc. Reports Third Quarter Fiscal 2025 Financial Results

~ Record Revenues of $664.2 million ~ ~ Record GAAP Diluted Earnings Per Share of $2.98 ~ NEW YORK, May 09, 2025--(BUSINESS WIRE)--Ubiquiti Inc. (NYSE: UI) ("Ubiquiti" or the "Company") today announced its financial results for the third quarter ended March 31, 2025. Third …

EODHD | 09 May 2025

Anika Reports First Quarter 2025 Financial Results

First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and …

EODHD | 09 May 2025

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

ALPHARETTA, Ga., May 09, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that six presentations related to the …

EODHD | 09 May 2025

We Think Deluxe's (NYSE:DLX) Solid Earnings Are Understated

Deluxe Corporation's (NYSE:DLX) recent earnings report didn't offer any surprises, with the shares unchanged over the last week. Our analysis suggests that shareholders might be missing some positive underlying factors in the earnings report. We've discovered 3 warning signs about Deluxe. View them for …

EODHD | 09 May 2025

Fortis Inc. Just Beat Revenue Estimates By 6.5%

As you might know, Fortis Inc. (TSE:FTS) just kicked off its latest first-quarter results with some very strong numbers. The company beat expectations with revenues of CA$3.3b arriving 6.5% ahead of forecasts. Statutory earnings per share (EPS) were CA$1.00, 3.1% ahead of estimates. This …

EODHD | 09 May 2025

Here's What Analysts Are Forecasting For TransDigm Group Incorporated (NYSE:TDG) After Its Second-Quarter Results

Shareholders might have noticed that TransDigm Group Incorporated (NYSE:TDG) filed its second-quarter result this time last week. The early response was not positive, with shares down 3.4% to US$1,385 in the past week. TransDigm Group reported US$2.2b in revenue, roughly in line with analyst …

EODHD | 09 May 2025

Premier, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Premier, Inc. (NASDAQ:PINC) defied analyst predictions to release its quarterly results, which were ahead of market expectations. The company beat forecasts, with revenue of US$261m, some 8.0% above estimates, and statutory earnings per share (EPS) coming in at US$0.31, 20% ahead of expectations. Following …

EODHD | 09 May 2025

UL Solutions Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Shareholders will be ecstatic, with their stake up 21% over the past week following UL Solutions Inc.'s (NYSE:ULS) latest quarterly results. The result was positive overall - although revenues of US$705m were in line with what the analysts predicted, UL Solutions surprised by delivering …

EODHD | 09 May 2025

Global Payments (NYSE:GPN) Has Affirmed Its Dividend Of $0.25

Global Payments Inc. (NYSE:GPN) will pay a dividend of $0.25 on the 27th of June. Based on this payment, the dividend yield on the company's stock will be 1.3%, which is an attractive boost to shareholder returns. Trump has pledged to "unleash" American oil …

EODHD | 09 May 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

Kymera Therapeutics, Inc. IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical …

EODHD | 09 May 2025
Support

Hi! How can we help you today?

Loading…